The immune system is able to recognize and eliminate tumor cells. Some tumors, including
colorectal cancer (CRC), induce immune tolerance via different mechanisms of …

Patients with recurring or metastatic colorectal cancer (mCRC) have strikingly low long-term
survival, while conventional treatments such as chemotherapeutic intervention and radiation …

Metastatic colorectal cancer (mCRC) is a leading cause of cancer-related mortality with a 5-
year overall survival rate of 13%. Despite recent advances in cancer immunotherapy, only …

Colorectal cancer (CRC) is one of the most common malignancies throughout the world and
the leading cause of cancer-related mortality in Western countries. Recent progress in CRC …

There are increasing incidences and mortality rates for colorectal cancer in the world. It is
common for chemotherapy and radiation given to patients with colorectal cancer to cause …

Colorectal cancer (CRC) is the leading cause of cancer death worldwide. CRC therapeutic
strategies include surgical resection, chemotherapy, radiotherapy, and other approaches …

Colorectal cancer is prevalent worldwide, with various factors influencing the survival rate of
late-stage metastatic cases. Current standard treatments include surgical removal, adjuvant …

Immunotherapy in the metastatic setting has drastically altered the landscape of treatment
for various types of malignancy, including colorectal cancer. The category of immune …

Colorectal cancer (CRC) is the second leading cause of cancer death in the world.
Immunotherapy using monoclonal antibodies, immune-checkpoint inhibitors, adoptive cell …

Colorectal cancer (CRC) is the third most common cancer globally and presents a significant
challenge owing to its high mortality rate and the limitations of traditional treatment options …